Influenza Virus-induced AP-1-dependent Gene Expression Requires Activation of the JNK Signaling Pathway*

Stephan LudwigDagger §, Christina EhrhardtDagger §, Elisabeth R. Neumeier||**, Michael KrachtDagger Dagger , Ulf R. RappDagger , and Stephan Pleschka||§§

From the Dagger  Institut für Medizinische Strahlenkunde und Zellforschung, Julius-Maximilians Universität, D-97078 Würzburg, Germany, || Institut für Mikrobiologie und Molekularbiologie, Justus-Liebig Universität, D-35392 Giessen, Germany, and Dagger Dagger  Institut für Pharmakologie, Medizinische Hochschule, D-30625 Hannover, Germany

Received for publication, October 31, 2000, and in revised form, December 20, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Influenza A virus infection of cells results in the induction of a variety of antiviral cytokines, including those that are regulated by transcription factors of the activating protein-1 (AP-1) family. Here we show that influenza virus infection induces AP-1-dependent gene expression in productively infected cells but not in cells that do not support viral replication. Among the AP-1 factors identified to bind to their cognate DNA element during viral infections of Madin-Darby canine kidney and U937 cells are those that are regulated via phosphorylation by JNKs. Accordingly, we observed that induction of AP-1-dependent gene expression correlates with a strong activation of JNK in permissive cells, which appears to be caused by viral RNA accumulation during replication. Blockade of JNK signaling at several levels of the cascade by transient expression of dominant negative kinase mutants and inhibitory proteins resulted in inhibition of virus-induced JNK activation, reduced AP-1 activity, and impaired transactivation of the IFN-beta promoter. Virus yields from transfected and infected cells in which JNK signaling was inhibited were higher compared with the levels from control cells. Therefore, we conclude that virus-induced activation of JNK and AP-1 is part of the innate antiviral response of the cell.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Influenza A virus is the prototype of the Orthomyxoviridae that are characterized by a segmented negative strand RNA genome. The function of the 10 different virus-encoded proteins has been well elucidated (reviewed in Ref. 1). Transcription and amplification of the viral genome is catalyzed by the RNA-dependent RNA polymerase (RDRP)1 complex, consisting of three proteins, PB2, PB1, and PA, which are associated with the ribonucleoprotein complex. Genomic influenza virus RNAs carry conserved nucleotide sequences at their 5'- and 3'-ends, which are in part complementary and serve as promoters for synthesis of both complementary RNA intermediates and novel viral RNA (vRNA) (1).

Because of the relatively small coding capacity of the viral genome, it is not surprising that influenza A viruses extensively manipulate and exploit host cell functions to support viral replication. On the other hand, the host cell has developed defense mechanisms against viral infections, which include an effective expression of antiviral cytokines that may require activation of cellular signaling pathways. Although only little is known about the intracellular signaling cascades that are activated by influenza virus, there are numerous reports on downstream target genes, such as interleukins (IL), tumor necrosis factor-alpha , and interferons (IFN), which are immediately transcribed in response to infection (for a review, see Ref. 2).

The best studied cell systems with respect to influenza virus-induced cellular gene expression are macrophages and monocytes. These cells are susceptible to influenza virus infection and express a set of cytokines such as tumor necrosis factor-alpha , IL-1, IL-6, and IFN-alpha /beta upon infection (3-5). Other virus-induced genes include monocyte chemoattractant protein-1 in monocytes (6) or IL-8 in human lung epithelial cells (7, 8) or rat kidney cells (9).

Several influenza virus-induced genes are dependent on activation of the AP-1 family of transcription factors, including the IFN-beta gene that encodes for one of the most potent antiviral cytokines. This transcription factor family consists of homodimers and heterodimers of Jun (c-Jun, JunB, JunD) Fos (c-Fos, FosB, Fra-1, Fra-2), or the activating transcription factor (ATF-2, ATF-3) proteins, which bind to a common DNA site, the AP-1 site (reviewed in Ref. 10). The regulation of AP-1 activity occurs at two major levels. First, the abundance of the proteins is commonly regulated by controlling the transcription of AP-1 factor genes (11). The regulation of transcription is best understood for c-jun and c-fos genes that are rapidly up-regulated upon cell stimulation (11). At a second level, the activity of different AP-1 factors is posttranscriptionally modulated by phosphorylation events. This includes AP-1 factors c-Jun and the constitutively expressed JunD and ATF-2, which are phosphorylated by kinases of the JNK family, resulting in an increased transactivation potential of the factors (reviewed in Refs. 10 and 12).

JNKs, also known as stress-activated protein kinases (SAPKs) belong to the family of mitogen-activated protein kinases (MAPKs) that are regulated by dual phosphorylation of threonine and tyrosine residues in a TXY motif (reviewed in Refs. 13 and 14). This activation is mediated by dual specificity kinases termed MAPK kinases (MKKs). For the JNK subgroup of MAPKs, at least two different MKKs have been identified as specific activators, MKK4/SEK (for SAPK/ERK kinase) (15) and MKK7 (16, 17). It was recently shown that MKK4 and MKK7 act synergistically in JNK activation, whereby MKK4 had a preference for the tyrosine residue and MKK7 for the threonine residue within the TXY motif (18). This suggests that the full activation of JNK may require phosphorylation by two different MKKs. Since MKK4 or MKK7 are preferentially activated by different upstream activators (19-21), there is the potential for integrating the effects of different extracellular signals. Specificity within the different signaling cascades is accomplished by scaffold proteins, such as the JNK-interacting protein-1 (JIP-1), which has been shown to form a complex with JNK, MKK7, and the MKK7 activator mixed lineage kinase (22).

In this report, we show that influenza virus infection of cells induces JNK activation and AP-1-dependent gene expression in a MKK4/SEK- and MKK7-dependent manner. This activation selectively occurs in cells permissive for virus replication and appears to be caused by accumulation of virus-specific RNA. Our findings link influenza virus replication to the activation of an important signaling pathway in the cell, which seems to be required for the antiviral response to infection.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Viruses, Cells, and Viral Infections-- Avian influenza virus A/Bratislava/79 (H7N7) (FPV), human influenza virus A/Asia/57 (H2N2) (Asia), and the reassortant virus WSN-HK (H1N2), which contains seven genes of human influenza A/WSN/33 (H1N1) and the neuraminidase gene from human influenza virus A/HK/8/68 (H3N2), were used for infection of different cell lines. Madin-Darby canine kidney (MDCK) cells were grown in minimal essential medium; the human cervical carcinoma cell line HeLa and human embryonic kidney HEK293 cells were grown in Dulbecco's modified Eagle's medium; U937 promonocytic cells and A3.01 human T lymphoma cells were grown in RPMI 1640 medium. All growth media contained 10% heat-inactivated fetal calf serum and antibiotics. Cells were washed with phosphate-buffered saline and infected with various viruses at the indicated multiplicity of infection (MOI) in phosphate-buffered saline/BA (phosphate-buffered saline containing 0.2% bovine serum albumin, 1 mM MgCl2, 0.9 mM CaCl2, 100 units/ml penicillin, 0.1 mg/ml streptomycin) for 30 min at 37 °C. The inoculum was aspirated, and cells were incubated with RPMI 1640/BA (U937 and A3.01 cells), minimal essential medium/BA (MDCK), or Dulbecco's modified Eagle's medium/BA (HEK293 and HeLa cells) (medium containing 0.2% bovine serum albumin and antibiotics). The amount of infectious virus grown in MDCK cells was determined by plaque assays.

DNA Constructs and Cloning-- Expression vectors for glutathione S-transferase (GST) fusion proteins pEBG-SAPKbeta , pEBG-SEK1 and pGEXKG-c-Jun-(1-135) were a kind gift of J. Kyriakis and L. Zon (Charlestown, MA). Generation of pEBG-SEK1(K>R) and pEBG-SAPKbeta (KK>RR) was described previously (23). The cDNAs of a hemagglutinin epitope (HA)-tagged version of SAPKbeta , the transactivation domain deletion mutant of c-Jun, TAM67, and the JNK binding domain of JIP-1 (22) were cloned into the multiple cloning site of pRSPA (24). Expression vectors pCS3 MKK7wt, MKK7(S3E), and MKK7(K>M) were a kind gift of P. M. Holland (Fred Hutchinson Cancer Research Center, Seattle, WA) and were described earlier (25). The 5× AP-1 luciferase construct contains five copies of a conserved 9-base pair AP-1 motif, also known as the TRE (12-O-tetradecanoylphorbol-13-acetate-responsive element) (26), in front of a luciferase reporter gene. The empty pHMG expression vector and pHMG expression plasmids for influenza virus NP, PB1, PB2, and PA were kindly provided by J. Pavlovic (Institute of Medical Virology, Zürich, Switzerland), and constructs that allow RNA polymerase I-driven synthesis of influenza vRNA-like templates carrying the antisense reading frame for a GFP (pPol I GFP) or a luciferase (pPol I Luc) reporter gene were kindly provided by P. Palese (Department of Microbiology, Mount Sinai School of Medicine, New York). The IFN-beta promoter/enhanceosome luciferase construct was a generous gift of J. Hiscott (Lady Davis Institute for Medical Research, McGill University, Montreal, Canada) (27). The double-stranded RNA (dsRNA) analog poly(IC) and the p38-specific inhibitor SB202190 were purchased from Sigma or Calbiochem, respectively.

Transient Transfections and Reporter Gene Assays-- Transfection of HEK293 cells was performed by a calcium phosphate coprecipitation method according to a modified Stratagene transfection protocol. A3.01 and U937 cells were transfected with DMRIE-C (Life Technologies), and MDCK and HeLa cells were transfected with FUGENE (Roche Molecular Biochemicals) or LipofectAMINE 2000 (Life Technologies) according to the manufacturer's instructions. Unless otherwise indicated, cells were harvested 24 h after transfection into 100 µl of lysis buffer (50 mM Na-MES, pH 7.8, 50 mM Tris-HCl, pH 7.8, 10 mM dithiothreitol, 2% Triton X-100). The crude cell lysates were cleared by centrifugation, and 50 µl of precleared cell extracts were added to 50 µl of luciferase assay buffer (125 mM Na-MES, pH 7.8, 125 mM Tris-HCl, pH 7.8, 25 mM magnesium acetate, 2 mg/ml ATP). Immediately after injection of 50 µl of 1 mM D-luciferin (AppliChem) into each sample, the luminescence was measured for 5 s in a luminometer (Berthold). As a transfection control, beta -galactosidase activity of cotransfected Rous sarcoma virus-beta -galactosidase vector was analyzed, and luciferase activities were normalized on the basis of protein content. Mean and S.D. values of at least three independent experiments performed in duplicate or triplicate are shown in Figs. 1, 6, and 8, A and B.

Electrophoretic Mobility Shift Assay (EMSA)-- Oligonucleotide probes derived from the IL-8 promoter AP-1 site as described (28) were labeled in a reaction mixture containing 200 ng of double-stranded DNA probe, [alpha -32P]dCTP, 1 mM dATP, 1 mM dGTP, 1 mM dTTP, 500 mM Tris-HCl, pH 7.5, 100 mM MgCl2, and 2 units of Klenow fragment. After a 30-min incubation at 37 °C, oligonucleotides were separated on a G-25 Sephadex spin column (Roche Molecular Biochemicals) and finally resuspended in TE (30,000 cpm/µl). For the typical binding reactions, 5 µg of nuclear lysates were incubated on ice for 5 min in the absence or presence of competitor DNA in an 18-µl reaction mixture containing 25 mM Tris, pH 7.5, 1 mM EDTA, 0.5 mM 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane, 100 mM KCl, 0.1% (v/v) Nonidet P-40, 1 µg (w/v) of bovine serum albumin, 10% (v/v) glycerol, and 0.5 µg (w/v) of poly(dI-dC); 60,000 cpm of labeled oligonucleotide were added, and the mixture was incubated for 15 min at 25 °C. The antisera for supershifts were all purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The samples were loaded on a 5% nondenaturing polyacrylamide gel equilibrated with 0.5× Tris borate-EDTA buffer and electrophoresed for 2.5 h at 180 V. Gels were dried, and DNA-protein complexes were visualized by autoradiography.

Immune Complex Kinase Assays and Western Blots-- Cells were lysed in Triton lysis buffer (20 mM Tris/HCl, pH 7.4, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 50 mM sodium glycerophosphate, 20 mM sodium pyrophosphate, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1 mM sodium vanadate, 5 mM benzamidine) on ice for 10-20 min. Cell lysates were then centrifuged, and supernatants were incubated with a specific antiserum and protein A-agarose (Roche Molecular Biochemicals) for 2 h at 4 °C to precipitate the endogenous kinase. Endogenous JNK1 was precipitated with an anti-JNK1 antiserum (Santa Cruz Biotechnology). Transfected HA- or GST-tagged SAPKbeta , GST-tagged SEK/MKK4, or Myc-tagged MKK7 were detected with either a monoclonal antibody against the HA epitope (12CA5), an antiserum against GST (23), or the monoclonal anti-Myc epitope antibody (9E10). Immune complexes were used for in vitro kinase assays as previously described (23). Briefly, immunoprecipitated kinases were washed twice, both in Triton lysis buffer supplemented with 500 mM NaCl and in kinase buffer (10 mM MgCl2, 25 mM beta -glycerophosphate, 25 mM HEPES pH 7.5, 5 mM benzamidine, 0.5 mM dithiothreitol, and 1 mM sodium vanadate). The assays were performed in kinase buffer supplemented with 5 µCi of [gamma -32P]ATP, 0.1 mM ATP, and recombinant GST-c-Jun-(1-135) or GST-SAPKalpha as substrates for JNK/SAPK or MKK4 and -7, respectively, at 30 °C for 15 min. Proteins were separated by SDS-polyacrylamide gel electrophoresis and blotted onto polyvinylidene difluoride membranes. Phosphorylated substrates were detected by a BAS 2000 Bio Imaging Analyzer (Fuji) and by autoradiography. Equal loading of immunoprecipitated kinases was analyzed by Western blotting using the appropriate anti-kinase antiserum or anti-tag antibody in a standard enhanced chemiluminescence reaction (Amersham Pharmacia Biotech). To detect activated ATF-2, an anti-phospho-ATF-2 antiserum was used (New England Biolabs). Equal ATF-2 loading in these assays was controlled with a pan-ATF-2 antiserum (Santa Cruz Biotechnology).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Influenza Virus Induces AP-1-dependent Gene Expression in Productively Infected Cells-- To selectively analyze the regulation of virus-induced AP-1-dependent gene expression without the involvement of other regulatory transcription factors, we used a promoter reporter gene construct containing five copies of an AP-1-binding DNA element in front of a luciferase reporter gene (26). Productive infection of MDCK cells with influenza A virus resulted in a virus titer-dependent transactivation of the AP-1 dependent promoter as early as 4 h postinfection (p.i.) (Fig. 1A). The early onset of luciferase expression suggests that the effects are directly induced by the virus and not by an autocrine event. Essentially the same results were obtained in the promonocytic U937 cell line, which is also permissive for influenza virus replication (Fig. 1B). In cells that only allow an abortive virus replication, such as T lymphocytes (A3.01) (29) or HeLa cells (30), the AP-1-dependent promoter activity remained completely silent (Fig. 1B), indicating that productive replication is required to induce AP-1-dependent transcription.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Productive influenza A virus infection results in transactivation of an AP-1 dependent promoter. MDCK cells (A) or U937, A3.01, and HeLa cells (B) were transfected with a 5× AP-1 luciferase construct and infected 24 h later with the influenza strain FPV at the MOIs indicated. Cells were harvested 4 or 8 h postinfection (p.i.), and luciferase activities in the lysates were determined as described. Results are given as -fold activation of relative luciferase activity compared with the uninfected control. HeLa cells were also infected with the Asia strain with essentially the same results (data not shown).

AP-1 Factors Are Constitutively Bound to Their Cognate DNA Element in MDCK and U937 Cells-- A first regulatory step in AP-1 activation is transcriptional up-regulation of different AP-1 components upon cell stimulation (10). To analyze whether influenza A virus infection results in an up-regulation of AP-1 factors, EMSAs from nuclear lysates of infected and noninfected MDCK cells were performed. Although there was a slight up-regulation of AP-1 factors 1-2 h after infection (Fig. 2A), the major portion of AP-1 factors was already bound to DNA in uninfected cells. Competition with the nonlabeled AP-1 DNA probe showed that the protein-DNA complexes observed were AP-1-specific (Fig. 2A). To analyze which AP-1 factors are constituents of the complex, supershift assays using specific antibodies against certain AP-1 proteins were performed. The shifted protein-DNA complexes in the presence of the antibodies indicated that c-Jun, c-Fos, and JunD were components of the AP-1 complexes. Further, with regard to these three factors, the composition of the AP-1 complexes did not differ 4 or 8 h postinfection (p.i.) (Fig. 2A). The same results were obtained with U937 cells, albeit in these cells more AP-1 specific complexes were observed (Fig. 2B). Furthermore, ATF-2 was identified as another AP-1 binding factor (Fig. 2C), while transcription factors JunB, Fra-1, and CREB did not bind to the AP-1-specific DNA probes in both cell lines (Fig. 2C and data not shown). Thus, c-Jun, c-Fos, JunD, and ATF-2 were identified as AP-1 binding factors in uninfected and infected cells and may contribute to the observed induction of AP-1-dependent transcription.



View larger version (82K):
[in this window]
[in a new window]
 
Fig. 2.   AP-1 factors are constitutively bound to AP-1 sites in MDCK and U937 cells during influenza A virus infection. MDCK (A) or U937 cells (B and C) were infected with FPV at a MOI of 5 for the times indicated, and nuclear lysates were subjected to EMSA using a labeled AP-1 DNA probe. Where indicated, binding reactions were performed in the presence of a 1:10 and 1:100 surplus of unlabeled oligonucleotides (competitor) or in the presence of specific antibodies against c-Jun, c-Fos, JunD, ATF-2, JunB, CREB-1, and Fra-1. As a control, nuclear lysate was replaced by H2O (A, lane 16). Roman numerals to the right of each panel are indicative of the main AP-1 complex (I) and the supershifted complexes induced after binding to the antibodies (II-V). p.i., postinfection.

ATF-2 Is Phosphorylated in Response to Virus Infection-- The transcriptional activity of AP-1 complexes is potentiated upon phosphorylation of AP-1 factors (10). One of these factors is ATF-2, which plays a critical role in the virus-induced expression of the antiviral cytokine IFN-beta (31, 32). ATF-2 was indeed phosphorylated upon infection with different influenza A virus strains in permissive 293 (Fig. 3A), COS7 (Fig. 3B), and U937 cells (data not shown). Two different MAPKs were reported to phosphorylate ATF-2, p38 and JNK/SAPK (33, 34). Although p38 is activated upon influenza virus infection (data not shown), ATF-2 phosphorylation was not decreased or abolished in cells treated with effective concentrations of the p38-specific inhibitor SB202190 (Fig. 3B). This indicates that the JNK/SAPK subgroup of MAPKs may be primarily responsible for the observed phosphorylation event.



View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   ATF-2 phosphorylation upon influenza virus infection occurs independently of p38 MAPK. 293 cells (A) or COS7 cells (B) were infected with the influenza strains FPV (A and B) or Asia (B) at a MOI of 8 for the times indicated in the presence (B) or absence (A and B) of the p38-specific inhibitor SB202190 (20 µM). Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membranes, and incubated with an antibody specific for phosphorylated ATF-2. Equal loading of ATF-2 was confirmed using a pan-ATF-2 antiserum. ATF-2 phosphorylation was also detected in lysates of virus-infected U937 cells with an earlier onset consistent with the kinetics of JNK activation in these cells (data not shown).

Productive Infection of Cells with Different Influenza A Viruses Results in a Strong Activation of JNK-- Since the data shown in Fig. 3B suggest that JNK causes virus-induced phosphorylation of ATF-2, we analyzed whether infection with different influenza A viruses results in JNK activation. Cells were infected and JNK activity was assessed in immune complex kinase assays at different time points postinfection. A strong activation of JNK was observed upon productive infection of MDCK, U937, or HEK293 cells. Activation kinetics did not differ between the virus isolates but were dependent on the cell line chosen. For example, infection of MDCK cells with the influenza A virus strain Asia (Fig. 4A), the FPV strain (Fig. 4B) or the reassortant virus WSN-HK (data not shown) resulted in an onset of JNK activation about 2-4 h postinfection, whereas the same virus isolates induced JNK activity only after 8 h postinfection in HEK293 cells. In U937 cells, JNK activation was observed as early as 1-2 h after infection with FPV. The dependence of virus-induced JNK activation on the cell type was most obvious in nonpermissive HeLa cells, where JNK was not activated at all (Fig. 4E). The same results were observed in Asia-infected A3.01 T lymphocytes (data not shown). This indicates that the potential of influenza A viruses to replicate in a certain cell type correlates with both the ability to induce JNK activity (Fig. 4) and AP-1-dependent gene expression (Fig. 1). In support of this assumption, we observed that inhibition of virus replication by the anti- influenza virus drug amantadine (35) results in a 50% decrease in JNK activity 8 h postinfection (Fig. 5A) concomitant with a roughly 50% reduction in virus titers analyzed in parallel.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   Influenza A virus induces a strong activation of JNK in productively infected cells. MDCK (A and B), HEK293 (C and D), HeLa (E), and U937 cells (F) were infected with Asia (A, C, and E) or FPV (B, D, and E) at a MOI of 5. Cells were harvested at the indicated times postinfection, and JNK1 was immunoprecipitated from cell lysates. Immune complexes were subjected to in vitro kinase assays using purified GST-c-Jun-(1-135) as a substrate. Proteins were separated by SDS-polyacrylamide gel electrophoresis, and labeled substrate bands were detected by exposure to x-ray films. Equal loading of JNK1 proteins was confirmed by Western blot.



View larger version (47K):
[in this window]
[in a new window]
 
Fig. 5.   Virus-induced activation of JNK/SAPK is mediated by MKK4/SEK and MKK7. A, MDCK cells were infected with FPV at an MOI of 8 for 8 h in the presence or absence of the anti-influenza viral compound amantadine (1 µM). The activity of endogenous JNK1 was determined as described. B, C, and D, HEK293 cells were transiently transfected with plasmids expressing GST-tagged wild type (SEK wt) or dominant negative SEK/MKK4 (SEK(K>R)) (B and D) or Myc-tagged wild type (MKK7 wt) or dominant negative MKK7 (MKK7(K>M)). 24 h after transfection, cells were infected for 8 h, and activity of transfected MKKs in the lysates was determined in immune complex kinase assays with GST-SAPKalpha (B and C) or in a coupled assay with GST-SAPKalpha and GST-c-Jun-(1-135) as substrates (D). E-G, HA-tagged JNK/SAPKbeta was cotransfected with vectors expressing MKK7(K>M), SEK(K>R), the JNK-binding domain of JIP-1, wild-type MKK7, or active MKK7(S3E) as indicated in a 1:1 (E-G) or 1:2 ratio (F). 24 h after transfection, cells were infected for 8 h, and cell lysates were used to immunoprecipitate JNK/SAPKbeta with an anti-HA antiserum. JNK/SAPKbeta activity was subsequently assayed in immune complex kinase assays as described. Loading of kinases was monitored by Western blot with the respective antibody. To quantify kinase activities in E, band intensities of phosphorylated c-Jun-(1-135) were normalized to the corresponding amount of immunoprecipitated JNK/SAPKbeta of each sample.

Virus-induced JNK Activation Is Mediated by MKK4/SEK and MKK7-- We next analyzed which known JNK activator(s) (MKK4/SEK, MKK7, or both) is activated in response to virus infection. Cells were transfected with vectors expressing tagged versions of either dominant negative or wild-type forms of SEK/MKK4 (Fig. 5B) or MKK7 (Fig. 5C). Cells were infected for 8 h, and transfected MKKs were specifically precipitated from cell lysates with the respective anti-tag antibody. Activities of SEK/MKK4 or MKK7 were then assessed in immune complex kinase assays using recombinant GST-tagged SAPKalpha , which is the rat isoform of JNK2, as a substrate. Both wild-type forms of SEK/MKK4 (Fig. 5B, lane 4) and MKK7 (Fig. 5C, lane 4) were activated upon infection, which was not the case in the control samples with the dominant negative kinases (Fig. 5, B and C, lane 2). To analyze whether the observed phosphorylation of GST-SAPKalpha was on the functional relevant sites, we performed a coupled assay by adding in recombinant GST-c-Jun-(1-135) as a substrate for GST-SAPKalpha to the sample. Indeed, GST-c-Jun-(1-135) was phosphorylated selectively in the samples corresponding to the infected cells (Fig. 5D, lanes 2 and 4), indicating that virus-induced activation of both MKK4 and -7 resulted in a functional phosphorylation of GST-SAPKalpha . For a further proof that SEK/MKK4 and MKK7 are upstream of JNK upon virus infection, the activity of the kinase was assessed in the presence of dominant negative forms of both MKKs. Fig. 5E shows that expression of both dominant negative MKK4/SEK (lane 3) and dominant negative MKK7 (lane 4) results in an inhibition of virus-induced activation of coexpressed HA-tagged JNK/SAPK. A concentration-dependent inhibition was not only observed by expression of SEK(K>R) but also of the JNK-binding domain of JIP-1 (Fig. 5F). Overexpressed JIP-1 inhibits JNK by competitive binding and retention in the cytoplasm (22). On the other hand, transient expression of wild-type MKK7 acts synergistically with virus infection to induce JNK/SAPK activity (Fig. 5G, lane 4). This indicates that the amounts of cellular MKK7 are limited and that the signal transmission is greatly enhanced if a surplus of the kinase is provided. Expression of an active mutant of MKK7 (MKK7(S3E)) resulted in a strong JNK activation already in the absence of virus, which is again significantly enhanced after infection (Fig. 5G, lanes 5 and 6), presumably due to the additional action of virus-activated MKK4/SEK. Taken together, virus infection induces the activity of both MKK4/SEK and MKK7, which act synergistically to activate JNK/SAPK.

Virus-induced Activation of AP-1-dependent Gene Expression Is Mediated by the JNK Signaling Pathway-- The observation that influenza virus infection causes activation of JNK/SAPK via MKK4 and MKK7 suggests that this pathway mediates AP-1-dependent gene expression. For a final proof, we measured virus-induced AP-1 dependent gene expression in the presence of transdominant interfering mutants of the JNK signaling cascade. Expression of dominant negative JNK/SAPK or a dominant negative form of c-Jun (TAM67) almost abolished luciferase expression induced by viral infection, suggesting that JNK/SAPK and its target transcription factor c-Jun are essential mediators of this process (Fig. 6A). As observed in the kinase assays (Fig. 5G), expression of MKK7wt and active MKK7(S3E) enhances the effect of virus infection on AP-1-dependent gene expression (Fig. 6B), whereas expression of the inhibitory mutant SEK(K>R) or JIP-1 results in an inhibition, both in U937 and MDCK cells (Fig. 6C). Thus, influenza virus-induced AP-1 dependent gene expression is regulated by MKK4/SEK and MKK7-mediated activation of JNK/SAPK and c-Jun.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Influenza A virus-induced AP-1-dependent gene expression is regulated by the JNK signaling pathway. U937 (A-C) and MDCK cells (C) were transfected with a 5× AP-1 luciferase construct and either cotransfected with empty expression vector (KRSPA or pCS3) or plasmids expressing dominant negative JNK/SAPK (SAPKbeta (KK>RR)) (A), dominant negative c-Jun (Tam67) (A), wild-type MKK7 (MKK7 wt) (B), constitutively active MKK7 (MKK7(S3E)) (B), dominant negative MKK4/SEK (SEK(K>R)) (C), or the JNK-binding domain of JIP-1 (C). Cells were infected 24 h later with the influenza strain FPV at a MOI of 5 and harvested 4 h postinfection (p.i.). Luciferase activities in the lysates were subsequently determined as described and are expressed as -fold activation compared with the uninfected control (A and B). In C, virus-induced AP-1 promoter activity in cells transfected with empty vectors is arbitrarily set as 100%, and relative luciferase activities are given in percentage of the control.

Accumulation of RNA Synthesized by the Viral Polymerase Complex Results in Activation of JNK-- A remaining question is which viral components are responsible for activation of JNK in the host cell. Recently, we identified influenza A virus hemagglutinin, nucleoprotein, and matrix protein as viral transactivators toward the transcription factor NF-kappa B (36). However, expression of these proteins resulted in neither the activation of JNK (data not shown) nor the activation of AP-1-dependent promoters (36). These studies were extended to the viral NS1 and NEP/NS2 proteins, which also did not induce JNK activity when overexpressed (data not shown). Another component of the virus is the single-stranded vRNA, which is transcribed and replicated by the viral RDRP complex consisting of the PB2, PB1, and PA proteins (1). The vRNA is transcribed into mRNA and amplified via a complementary RNA replication intermediate. To assess whether dsRNA has the capacity to induce JNK signaling, we treated MDCK cells with the dsRNA analog, poly(IC). Indeed, poly(IC) stimulation induced a time- and concentration-dependent activation of JNK (Fig. 7A), which was not inhibited by actinomycin D or cycloheximide (data not shown). This indicates that activation occurs directly and does not involve new RNA or protein synthesis. To analyze whether accumulation of influenza-like RNAs gives rise to JNK activation, we used a plasmid-based replication system for vRNA-like RNA polymerase I (Pol I) transcripts. Briefly, cells were transfected with expression plasmids for the RDRP constituents PB2, PB1, PA, and NP and for a vRNA-like Pol I transcript carrying the conserved 5' and 3' promoter structures of influenza vRNA segments flanking an antisense reporter gene. Such constructs have been successfully used to provide vRNA-like templates for the RDRP in plasmid-derived reverse genetics approaches (37). In these studies, it was demonstrated that all three polymerase genes as well as the NP gene have to be cotransfected to allow transcription and amplification of the reporter gene template (37). Using GFP as a reporter gene (pPol I GFP) ~5-10% of transfected cells showed green fluorescence after cotransfection of plasmids expressing PB2, PB1, PA, and NP, while no green cells were detectable if either the plasmids for NP or the template vRNA were replaced by empty vectors (data not shown). This indicates that only 5-10% of transfected cells carry all of the plasmids required for transcription and amplification of the template vRNA. Nevertheless, we observed a significant activation of GST-SAPKbeta in the samples cotransfected with all essential replicase genes and either pPol I GFP or pPol I Luc plasmids expressing template vRNAs (Fig. 7B, lanes 3 and 6). No SAPKbeta activation was detectable if either NP (Fig. 7B, lane 2) or the template RNAs were omitted (Fig. 7B, lane 4) or replaced by empty pPol I vectors (Fig. 7B, lanes 5 and 7). These findings demonstrate that JNK/SAPK is activated during influenza virus-specific transcription and replication of an influenza-like RNA template by the viral RDRP complex, suggesting that vRNA accumulation is the trigger for activation of the JNK signaling pathway.



View larger version (39K):
[in this window]
[in a new window]
 
Fig. 7.   Poly(IC) treatment of cells or amplification of an influenza vRNA-like segment by a reconstituted RDRP complex results in JNK activation. A, MDCK cells were treated with the dsRNA analog poly(IC) at the concentrations and for the times indicated. JNK activity was assessed in the cell lysates as previously described. B, MDCK cells were transfected with expression plasmids for GST-SAPKbeta , PB2, PB1, PA, and NP. Equal DNA load was adjusted with empty expression vector. To provide template RNAs for the RDRP plasmids expressing Flu-like RNA containing a GFP or luciferase antisense reporter gene (pPol I GFP and pPol I Luc) were cotransfected. In the samples indicated, the RNA template constructs were replaced by the corresponding empty vector (pPol I vector). Proper function of the influenza replicase complex was monitored by the count of GFP-positive cells. Note that only 5-10% of transfected cells contained all plasmids for transcription and expression of GFP. 24 h posttransfection, cells were harvested, and lysates were assayed for GST-SAPKbeta activity as described.

The JNK Signaling Pathway Is Critical for Virus-induced Activation of the IFN-beta Promoter-- IFN-beta is one of the most potent antiviral cytokines. The IFN-beta promoter/enhanceosome was shown to bind c-Jun/ATF-2 heterodimers, which are essential for the virus-induced transcription of the cytokine gene (31). To finally analyze whether virus-induced IFN-beta expression is dependent on the JNK signaling pathway, we cotransfected dominant negative mutants of JNK/SAPK (SAPKbeta (KK>RR)) or c-Jun (TAM67) with an IFN-beta promoter luciferase construct. Both, treatment with poly(IC) and infection with influenza A virus, resulted in a strong transactivation of the IFN-beta promotor, which was efficiently blocked in the presence of dominant negative JNK/SAPK or c-Jun (Fig. 8, A and B). These data demonstrate that JNK/SAPK is essential for RNA- or influenza virus-induced transcription of the cytokine gene. Since the JNK pathway appears to regulate the expression of an efficient antiviral cytokine, inhibition of the pathway should increase the ability of the virus to replicate in cells. Indeed, higher virus yields were obtained in infected MDCK expressing dominant negative mutants of either MKK7, JNK/SAPK, or c-Jun (Fig. 8C). Taken together, these data suggest that activation of the JNK signaling pathway and AP-1-dependent gene expression upon influenza virus infection are part of the innate immune response of the cell, e.g. by triggering expression of antiviral cytokines such as IFN-beta .



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 8.   Influenza A virus-induced expression of IFN-beta is regulated by the JNK signaling pathway. A and B, MDCK cells were transfected with an IFN-beta promoter/enhanceosome luciferase construct and cotransfected with either empty expression vector or plasmids expressing dominant negative JNK/SAPK (SAPKbeta (KK>RR)) or dominant negative c-Jun (TAM67). 24 h posttransfection, cells were either treated with poly(IC) (50 µg/ml) (A) for 6 h or infected with FPV for 4 h (B). Luciferase activity in the cell lysates was determined as described under "Experimental Procedures." C, MDCK cells were transfected with empty expression vector or plasmids expressing dominant negative JNK/SAPK (SAPKbeta (KK>RR)), dominant negative c-Jun (TAM67), or dominant negative MKK7 (MKK7(K>M)). Transfection efficiency was monitored by GFP expression to be 50-60%. 9 h postinfection, supernatants were analyzed for the amount of infectious virus particles released in conventional plaque assays. Virus yield in vector transfected cells was arbitrarily set as 100%. Experiments were performed twice in duplicate.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The elucidation of intracellular signaling pathways that are activated by influenza A virus infection is important for the understanding of both viral replication strategies and host defense mechanisms. Here we show that productive infection of cells results in a strong activation of the JNK subgroup of MAPK signaling pathways. Further, expression of dominant interfering mutants revealed that the JNK signaling pathway is a major player in transduction of virus-induced signals leading to AP-1-dependent expression of IFN-beta . Thus, virus-induced activation of JNK and AP-1 appears to be part of the innate antiviral response of the host cell.

AP-1 family transcription factors are regulated both on a transcriptional and posttranslational level (10). Our results demonstrate that transcriptional up-regulation of AP-1 factors only plays a minor role for influenza virus-induced AP-1-dependent gene expression in MDCK and U937 cells. In both uninfected and infected cells, the major portion of AP-1 components were constitutively bound to AP-1 sites, and the composition of the complexes was not significantly changed during infection (Fig. 2). This is consistent with the appearance of constitutively expressed JunD and ATF-2 in the complex. The weak up-regulation 1-2 h after infection (Fig. 2) may be attributed to c-Jun and c-Fos that were also identified in the complexes. It is still an open question which virus-induced signaling events are responsible for the observed up-regulation of these factors. Recently, it was shown that pharmacological inhibition of the mitogenic Raf/MEK/ERK signaling cascade at the level of MEK results in a block of 12-O-tetradecanoylphorbol-13-acetate-induced c-Jun and c-Fos mRNA synthesis (38). Using the same inhibitor, U0126, in EMSA experiments, we could not interfere with influenza virus-induced up-regulation of AP-1 factors,2 although we observed an activation of the Raf/MEK/ERK cascade early after infection (39). Given that a variety of signaling pathways are known to be involved in regulation of AP-1 factor expression (40), inhibition of MEK by U0126 may not be sufficient to result in detectable differences in the EMSA.

In an analysis of the viral features that give rise to the strong JNK activation, we have now identified accumulation of virus-specific RNA as a major trigger. This finding is consistent with two other reports published while this manuscript was in preparation (41, 42). In these studies, it was shown that treatment with the dsRNA analog poly(IC) as well as infection with vesicular stomatitis virus (41) or encephalomyocarditis virus (42) results in JNK activation. However, poly(IC) might have its limitations to represent RNA of replicating single-stranded RNA viruses. In our study, we have reconstituted the influenza virus replicase complex to mimic ongoing viral genome transcription and replication in the absence of infection. This is the first demonstration that RNA accumulation within a virus-like setting causes activation of the JNK signaling cascade. This finding further indicates that viral RNA still has signaling capacity, although it is packaged with NP to form RNP complexes. It will now be important to identify the direct cellular signaling sensors for viral RNA. The only cellular signaling enzyme known so far to be directly regulated by dsRNA is the 68-kDa double-stranded RNA-dependent kinase (43), which inhibits protein synthesis by phosphorylation of the alpha -subunit of the eukaryotic initiation factor 2 (44). It was recently shown that virus-induced activation of Ikappa B kinase and NF-kappa B is dependent on RNA-dependent kinase activity; however, JNK was activated independently of RNA-dependent kinase in these studies (41). Our experiments indicate that influenza A virus-induced AP-1 activation is mediated by JNK and its upstream activators MKK4/SEK and MKK7. A variety of kinases that are direct upstream activators of MKK7 and MKK4/SEK are known (45) and may be involved in virus-induced JNK activation, but none of these kinases had so far been shown to be activated by dsRNA. Thus, the search is open for a dsRNA-regulated enzyme upstream of MKK4/SEK and MKK7.

Usually, 5-6 h after infection with influenza A virus, an efficient host-cell protein synthesis shut off is initiated (1). The induction of JNK activity 2-4 h postinfection and the amount of luciferase that is accumulated as early as 4 h postinfection show that the viral induction of both AP-1-dependent gene expression and transactivation of the IFN-beta promoter occur before the protein-synthesis block. The late virus-induced activity of JNK at 8-10 h postinfection may only poorly contribute to gene expression events. Although this late activation phase is not counteracted by the virus, it may not positively interfere with virus replication, since cells in which JNK signaling is impaired allowed a more efficient virus propagation (Fig. 8C).

Another interesting observation is the inability of nonpermissive cells, such as T lymphocytes or HeLa cells, to support virus-induced JNK1 and AP-1 activation. These cells are readily infected; however, they undergo an abortive infection at some point during the viral life cycle. In HeLa cells, synthesis of viral proteins was found to be normal, but there appears to be a defect during budding of novel virus particles (46), presumably due to a misincorporation of the HA into the membrane (47). In T lymphocytes, the point at which viral replication is impaired is less well understood; however, there is also a significant amount of viral proteins synthesized without formation of new virus particles (29). It will now be of great interest to elucidate why there is a lack of JNK activation despite the fact that virus-specific RNA is still synthesized in these cells.

In summary, our results demonstrate for the first time that productive influenza A virus infection results in the activation of a member of the MAPK signaling cascades, which are important mediators of intracellular signaling. Virus-induced activation of AP-1-dependent gene expression occurs early during the viral life cycle, is mediated by viral RNA-induced activation of the JNK signaling cascade, and appears to be part of the innate immune response to infection.


    ACKNOWLEDGEMENTS

We thank Heide Häfner and Irina Böhle for excellent technical assistance and Alex McLellan, Gaby Neumann, Oliver Planz, Christoph Scholtissek, and Thorsten Wolff for critical reading of the manuscript. We are very grateful to P. Holland, J. Kyriakis, P. Palese, J. Pavlovic, and L. Zon for providing plasmids.


    FOOTNOTES

* This work was supported by Deutsche Forschungsgemeinschaft Grant Lu 477/4-3 and a grant from the Fonds der Chemischen Industrie (to S. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

To whom correspondence should be addressed: Institut für Medizinische Strahlenkunde und Zellforschung, Julius-Maximilians Universität Würzburg, Versbacher Strasse 5, D-97078 Würzburg, Germany. Tel.: 49 931 201 3851; Fax: 49 931 201 3835; E-mail: s.ludwig@mail.uni-wuerzburg.de.

** Present address: SmithKline Beecham Pharma, Sächsische Serumwerke, D-01069 Dresden, Germany.

§§ Present address: Institut für Virologie, Fachbereich Veterinärmedizin, Justus-Liebig Universität, D-35392 Giessen, Germany.

Published, JBC Papers in Press, January 9, 2001, DOI 10.1074/jbc.M009902200

2 C. Ehrhardt and S. Ludwig, unpublished results.


    ABBREVIATIONS

The abbreviations used are: RDRP, RNA-dependent RNA polymerase; AP-1, activating protein-1; ATF, activating transcription factor; JNK, Jun-N-terminal kinase; MDCK, Madin-Darby canine kidney; MKK, MAPK kinase; vRNA, viral RNA; dsRNA, double-stranded RNA; IL, interleukin; IFN, interferon; SAPK, stress-activated protein kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase, SEK, SAPK/ERK kinase; JIP-1, JNK-interacting protein-1, GFP, green fluorescent protein; MOI, multiplicity of infection; GST, glutathione S-transferase; HA, hemagglutinin; MES, 4-morpholineethanesulfonic acid; EMSA, electrophoretic mobility shift assay; Pol I, polymerase I.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Lamb, R. A., and Krug, R. M. (1996) in Fields Virology (Fields, B. N., ed), 3rd Ed. , pp. 1353-1395, Lippincott-Raven Publishers, Philadelphia
2. Ludwig, S., Pleschka, S., and Wolff, T. (1999) Viral Immunol. 12, 175-196[Medline] [Order article via Infotrieve]
3. Roberts, N. J., Jr., Prill, A. H., and Mann, T. N. (1986) J. Exp. Med. 163, 511-519[Abstract]
4. Nain, M., Hinder, F., Gong, J. H., Schmidt, A., Bender, A., Sprenger, H., and Gemsa, D. (1990) J. Immunol. 145, 1921-1928[Abstract/Free Full Text]
5. Bender, A., Amann, U., Jager, R., Nain, M., and Gemsa, D. (1993) J. Immunol. 151, 5416-5424[Abstract/Free Full Text]
6. Sprenger, H., Meyer, R. G., Kaufmann, A., Bussfeld, D., Rischkowsky, E., and Gemsa, D. (1996) J. Exp. Med. 184, 1191-1196[Abstract]
7. Choi, A. M., and Jacoby, D. B. (1992) FEBS Lett. 309, 327-329[CrossRef][Medline] [Order article via Infotrieve]
8. Matsukura, S., Kokubu, F., Noda, H., Tokunaga, H., and Adachi, M. (1996) J. Allergy Clin. Immunol. 98, 1080-1087[Medline] [Order article via Infotrieve]
9. Ochiai, H., Ikesue, A., Kurokawa, M., Nakajima, K., and Nakagawa, H. (1993) J. Virol. 67, 6811-6814[Abstract]
10. Karin, M., Liu, Z., and Zandi, E. (1997) Curr. Opin. Cell Biol. 9, 240-246[CrossRef][Medline] [Order article via Infotrieve]
11. Karin, M. (1995) J. Biol. Chem. 270, 16483-16486[Free Full Text]
12. Whitmarsh, A. J., and Davis, R. J. (1996) J. Mol. Med. 74, 589-607[CrossRef][Medline] [Order article via Infotrieve]
13. Robinson, M. J., and Cobb, M. H. (1997) Curr. Opin. Cell Biol. 9, 180-186[CrossRef][Medline] [Order article via Infotrieve]
14. Ip, Y. T., and Davis, R. J. (1998) Curr. Opin. Cell Biol. 10, 205-219[CrossRef][Medline] [Order article via Infotrieve]
15. Sanchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. (1994) Nature 372, 794-798[Medline] [Order article via Infotrieve]
16. Tournier, C., Whitmarsh, A. J., Cavanagh, J., Barrett, T., and Davis, R. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7337-7342[Abstract/Free Full Text]
17. Holland, P. M., Suzanne, M., Campbell, J. S., Noselli, S., and Cooper, J. A. (1997) J. Biol. Chem. 272, 24994-24998[Abstract/Free Full Text]
18. Lawler, S., Fleming, Y., Goedert, M., and Cohen, P. (1998) Curr. Biol. 8, 1387-1390[Medline] [Order article via Infotrieve]
19. Cuenda, A., and Dorow, D. S. (1998) Biochem. J. 333, 11-15[Medline] [Order article via Infotrieve]
20. Yamauchi, J., Kaziro, Y., and Itoh, H. (1999) J. Biol. Chem. 274, 1957-1965[Abstract/Free Full Text]
21. Merritt, S. E., Mata, M., Nihalani, D., Zhu, C., Hu, X., and Holzman, L. B. (1999) J. Biol. Chem. 274, 10195-10202[Abstract/Free Full Text]
22. Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J. R., Greenberg, M. E., Sawyers, C. L., and Davis, R. J. (1997) Science 277, 693-696[Abstract/Free Full Text]
23. Ludwig, S., Engel, K., Hoffmeyer, A., Sithanandam, G., Neufeld, B., Palm, D., Gaestel, M., and Rapp, U. R. (1996) Mol. Cell. Biol. 16, 6687-6697[Abstract]
24. Dorn, P., DaSilva, L., Martarano, L., and Derse, D. (1990) J. Virol. 64, 1616-1624[Medline] [Order article via Infotrieve]
25. Holtmann, H., Winzen, R., Holland, P., Eickemeier, S., Hoffmann, E., Wallach, D., Malinin, N. L., Cooper, J. A., Resch, K., and Kracht, M. (1999) Mol. Cell. Biol. 19, 6742-6753[Abstract/Free Full Text]
26. Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., and Karin, M. (1987) Cell 49, 729-739[Medline] [Order article via Infotrieve]
27. Leblanc, J. F., Cohen, L., Rodrigues, M., and Hiscott, J. (1990) Mol. Cell. Biol. 10, 3987-3993[Medline] [Order article via Infotrieve]
28. Kunz, M., Hartmann, A., Flory, E., Toksoy, A., Koczan, D., Thiesen, H. J., Mukaida, N., Neumann, M., Rapp, U. R., Brocker, E. B., and Gillitzer, R. (1999) Am. J. Pathol. 155, 753-763[Abstract/Free Full Text]
29. Brownson, J. M., Mahy, B. W., and Hazleman, B. L. (1979) Infect. Immun. 25, 749-756[Medline] [Order article via Infotrieve]
30. Caliguiri, L. A., and Holmes, K. V. (1979) Virology 92, 15-30[Medline] [Order article via Infotrieve]
31. Du, W., and Maniatis, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2150-2154[Abstract]
32. Wathelet, M. G., Lin, C. H., Parekh, B. S., Ronco, L. V., Howley, P. M., and Maniatis, T. (1998) Mol. Cell 1, 507-518[Medline] [Order article via Infotrieve]
33. Livingstone, C., Patel, G., and Jones, N. (1995) EMBO J. 14, 1785-1797[Abstract]
34. van Dam, H., Wilhelm, D., Herr, I., Steffen, A., Herrlich, P., and Angel, P. (1995) EMBO J. 14, 1798-1811[Abstract]
35. Hay, A. J., Wolstenholme, A. J., Skehel, J. J., and Smith, M. H. (1985) EMBO J. 4, 3021-3024[Abstract]
36. Flory, E., Kunz, M., Scheller, C., Jassoy, C., Stauber, R., Rapp, U. R., and Ludwig, S. (2000) J. Biol. Chem. 275, 8307-8314[Abstract/Free Full Text]
37. Pleschka, S., Jaskunas, R., Engelhardt, O. G., Zurcher, T., Palese, P., and Garcia-Sastre, A. (1996) J. Virol. 70, 4188-4192[Abstract]
38. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. (1998) J. Biol. Chem. 273, 18623-18632[Abstract/Free Full Text]
39. Pleschka, S., Wolff, T., Ehrhardt, C., Hobom, G., Planz, O., Rapp, U. R., and Ludwig, S. (2001) Nat. Cell Biol. 3, 301-305[CrossRef][Medline] [Order article via Infotrieve]
40. Marinissen, M. J., Chiariello, M., Pallante, M., and Gutkind, J. S. (1999) Mol. Cell. Biol. 19, 4289-4301[Abstract/Free Full Text]
41. Chu, W. M., Ostertag, D., Li, Z. W., Chang, L., Chen, Y., Hu, Y., Williams, B., Perrault, J., and Karin, M. (1999) Immunity 11, 721-731[Medline] [Order article via Infotrieve]
42. Iordanov, M. S., Paranjape, J. M., Zhou, A., Wong, J., Williams, B. R., Meurs, E. F., Silverman, R. H., and Magun, B. E. (2000) Mol. Cell. Biol. 20, 617-627[Abstract/Free Full Text]
43. Williams, B. R. (1999) Oncogene 18, 6112-6120[CrossRef][Medline] [Order article via Infotrieve]
44. de Haro, C., Mendez, R., and Santoyo, J. (1996) FASEB. J. 10, 1378-1387[Abstract/Free Full Text]
45. Fanger, G. R., Gerwins, P., Widmann, C., Jarpe, M. B., and Johnson, G. L. (1997) Curr. Opin. Genet. Dev. 7, 67-74[CrossRef][Medline] [Order article via Infotrieve]
46. Gujuluva, C. N., Kundu, A., Murti, K. G., and Nayak, D. P. (1994) Virology 204, 491-505[CrossRef][Medline] [Order article via Infotrieve]
47. Portincasa, P., Conti, G., and Chezzi, C. (1990) Virus Res. 18, 29-40[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.